Volume 9 — September 27, 2012
CME ACTIVITY
Factors Associated With Poor Glycemic Control or Wide Glycemic Variability Among Diabetes Patients in Hawaii, 2006–2009
| Age, y | Level of Glycemic Control | P Value | |||
|---|---|---|---|---|---|
| Good (n = 166), % | Poor (n = 2,034), % | Wide Variability (n = 76), % | Some Variability (n = 694), % | ||
| <35 | 2.4 | 4.8 | 9.2 | 2.2 | <.001 |
| 35–49 | 22.3 | 24.0 | 29.0 | 18.6 | |
| 50–64 | 50.6 | 50.2 | 39.5 | 49.0 | |
| 65–79 | 18.7 | 17.0 | 18.4 | 23.9 | |
| ≥80 | 6.0 | 3.9 | 3.9 | 6.3 | |
Figure 1. Glycemic control related to age in patients with diabetes, unadjusted, Hawaii, 2006–2009. Good control indicated by an HbA1c of less than 7% for 3 years, and poor control indicated by an HbA1c higher than 9% for 3 years. Wide glycemic variability refers to patients who had a reduction in annual mean HbA1c from higher than 9% to less than 7%, followed by an increase to higher than 9%. Some variability refers to patients who did not meet criteria for the other 3 categories. Glycemic control differed significantly by age (P < .001, Pearson χ2 tests).
| Diabetes Duration, y | Level of Glycemic Control | P Value | |||
|---|---|---|---|---|---|
| Good (n = 166), % | Poor (n = 2,034), % | Wide Variability (n = 76), % | Some Variability (n = 694), % | ||
| ≥10 | 32.5 | 56.7 | 50.0 | 51.6 | <.001 |
| 8–9 | 12.1 | 13.8 | 13.2 | 13.8 | |
| 6–7 | 9.0 | 14.0 | 11.8 | 13.11 | |
| 4–5 | 13.9 | 8.7 | 7.9 | 10.1 | |
| 1–3 | 32.5 | 6.8 | 17.1 | 11.4 | |
Figure 2. Glycemic control related to duration of diabetes in patients with diabetes, unadjusted, Hawaii, 2006–2009. Good control was indicated by an HbA1c of less than 7% for 3 years, and poor control was indicated by an HbA1c higher than 9% for 3 years. Wide glycemic variability refers to patients who had a reduction in annual mean HbA1c from higher than 9% to less than 7%, followed by an increase to higher than 9%. Some variability refers to patients who did not meet criteria for the other 3 categories. Glycemic control differed significantly by duration of diabetes (P < .001, Pearson χ2 tests).
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.
